Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
Profitability
This table compares Achieve Life Sciences and OmniAb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Achieve Life Sciences | N/A | -193.49% | -111.88% |
| OmniAb | -187.59% | -20.31% | -18.10% |
Risk & Volatility
Achieve Life Sciences has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achieve Life Sciences | N/A | N/A | -$54.65 million | ($1.12) | -4.07 |
| OmniAb | $18.67 million | 19.77 | -$64.78 million | ($0.46) | -5.54 |
Achieve Life Sciences has higher earnings, but lower revenue than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 3.0% of Achieve Life Sciences shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for Achieve Life Sciences and OmniAb, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achieve Life Sciences | 1 | 0 | 3 | 2 | 3.00 |
| OmniAb | 1 | 0 | 2 | 0 | 2.33 |
Achieve Life Sciences currently has a consensus target price of $14.67, suggesting a potential upside of 221.64%. OmniAb has a consensus target price of $3.00, suggesting a potential upside of 17.65%. Given Achieve Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than OmniAb.
Summary
Achieve Life Sciences beats OmniAb on 8 of the 14 factors compared between the two stocks.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
